Fig 2: (a) The impact of LB51 and LB63 versus LB51(Ac)2–Cbz and LB63(Ac)2–Cbz on the Hsp90-Cyp40 interaction. Experiments were conducted in triplicate and data represent mean ± SEM of at least two independent experiments. (b) Competitive assays where LB51-Tag is competing for binding with LB51(Ac)2–Cbz, or LB63(Ac)2–Cbz to the C-terminal domain of Hsp90. Experiments were conducted in duplicate and data represent mean ± SEM of two independent experiments.

Fig 3: Lead inhibitors: 12-amino acid TPR peptide that binds to Hsp90 and LB51 lead scaffold derived from truncated sequence of TPR peptide.

Fig 4: (a) Structures of LB51 analogs, where each position is substituted with alanine, lysine, or the d-isomer. (b) Impact of analogs on Hsp90–Cyp40 interaction.